

UK: +44 (0)207 989 0813 NA: +1 646 896 3065 AU +61 2 9280 0700 action@proactiveinvestors.com.au

Cellmid Ltd

12:47 24 Oct 2017

Cellmid to benefit from share consolidation as revenues grow

Cellmid Ltd (ASX:CDY) is proposing a consolidation of its securities at the ratio of 20 to 1 during the upcoming Annual General Meeting.

The consolidation with reduce share price volatility and reduce administration costs.

It will also attract a broader range of investors, as many are reluctant to invest in lower priced shares and often have investment restrictions to invest in such companies.

Dr David King, chairman, commented:

"The proposed 20:1 consolidation is an essential next step on the path to secure the long-term success of Cellmid and it is expected to benefit all shareholders."

Attracting partners

In 2016, the board developed a series of strategic initiatives, with the midkine and consumer health businesses being separated into their wholly-owned operational entities, Lyramid, Kinera and Advangen.

The benefits of this operational split have already started to show as partnering and funding discussions are in progress for the standalone businesses.

Therefore, potential partners for the company's drug development are not distracted by the consumer health business, and vice versa.

READ NOW: Cellmid delivers positive results using the evolis® Professional product range

A\$0.52 **Market Cap:** A\$29.59M 1 Year Share Price Graph @ Digital Look 0.8 0.7 0.6 0.5 0.4 0.3 Share Information 2018 Code: CDY Listing: **ASX** 52 week High Low **0.8p** 0.35pPharma & Biotech Sector: Website: www.cellmid.com.au **Company Synopsis:** Cellmid Ltd (ASX:CDY) is listed on the Australian Securities Exchange. Author: **Proactive Investors Australia** +61 (0)2 9280 0700

action@proactiveinvestors.com.au

Price:

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors. private client brokers. international investor communities. fund managers and

> +61 (0)2 9280 0700 action@proactiveinvestors.com.au Contact us

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.



You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.